Arcturus Therapeutics Reports 93% Revenue Plunge, Doubled Net Loss, and Ongoing Arbitration with CSL Seqirus

summarizeSummary

Arcturus Therapeutics announced a 93% drop in Q1 2026 revenue and a near-doubling of its net loss, alongside an ongoing arbitration with CSL Seqirus, signaling significant financial challenges and increased uncertainty.

check_boxKey Events

• Revenue Plummets 93%

  Total revenue for Q1 2026 decreased by $27.3 million, or 93%, to $2.061 million, compared to $29.382 million in Q1 2025, primarily due to reduced collaboration and grant revenue.

• Net Loss Nearly Doubles

  The company reported a net loss of $26.964 million in Q1 2026, a significant increase from the $14.076 million net loss in Q1 2025.

• Arbitration with CSL Seqirus Over Milestone Payment

  Arcturus initiated arbitration against CSL Seqirus in May 2025, seeking payment of a milestone related to KOSTAIVE's EU marketing authorization. CSL Seqirus is contending it has no current obligation to pay.

• Clinical Pipeline Updates

  LUNAR-CF (ARCT-032) Phase 2 enrollment and dosing completed for initial cohorts with generally safe results, and a fourth cohort is now enrolling. For LUNAR-OTC (ARCT-810), the FDA provided a path forward for a pivotal pediatric study, requiring additional exploratory data.

auto_awesomeAnalysis

Arcturus Therapeutics reported a severe financial deterioration in Q1 2026, with total revenue plummeting 93% year-over-year and net loss nearly doubling. This significant decline, following a major write-down by partner CSL Seqirus in the prior fiscal year, raises substantial concerns about the company's near-term financial performance and reliance on future collaborations. The ongoing arbitration with CSL Seqirus over a milestone payment adds further uncertainty and legal risk. While clinical programs show some progress, the financial results and legal dispute are highly material and could impact investor confidence and future financing efforts. The company acknowledges the need for additional capital despite stating a 12-month cash runway.